Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Neratinib, and Paclitaxel in HER-mutated Gastric Cancer
NCT05512182Phase 2Withdrawn
- Sponsor
- Yonsei University
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib, pembrolizumab in gastric cancer (GC), sponsored by Yonsei University. Planned start Sep 2022; status: withdrawn.
02
Drugs
neratinibpembrolizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05512182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512182.